Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IMMX vs IBO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IMMX 1 – 4 IBO (1 Tie) Matrix Metrics: IMMX 4 – 5 IBO

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Immix Biopharma, Inc. (IMMX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMMX carries a Unified Composite Score of 48.6/100 (HOLD) at $7.48 (N/M Forward P/E, 0.0% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin).

  • Composite vs. Pillar Nuance: While IMMX currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMMX vs IBO
IMMX NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.48
-4.59% 1D
Market Cap $657.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.80β · 84% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 46.0 Fund 55.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $8.05 · SMA50: $9.69
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
TTM Revenue $2.6M
Forward P/E N/M
Beta / 30D Vol -6.72β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52

6-Pillar Scorecard Institutional Category Breakdown (IMMX 1 – 4 IBO)

Columns: Metric · IMMX · IBO
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue N/M 17.4x
2. Growth & Scale IBO
Revenue Growth (YoY) +0.0% +16.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $2.6M
Market Cap $657.1M $44.4M
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin 0.0% -12621.0%
Net Profit Margin 0.0% 4247.4%
Return on Equity (ROE) -27.0% 71.2%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$39M -$284M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $224M Net Cash $1.18 Book/Sh · 71.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMMX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.6% (17th %ile) N/A (N/A)
Put/Call OI Skew 1.24x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMMX (4) vs IBO (5)
Institutional Metric IMMX IBO Criterion Row Edge
Market Capitalization
Scale
$657.1M $44.4M Larger Scale IMMX
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +16.7% Higher Growth IBO
Operating Margin (TTM)
Profitability
0.0% -12621.0% Higher Margin IMMX
Net Profit Margin
Profitability
0.0% 4247.4% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
-27.0% 71.2% Higher ROE IBO
52-Week Range Position
Momentum
35% ($3–$15) 67% ($0–$7) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
1.80β · 84% Vol -6.72β · 120% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 17.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$39M ($224M Net Cash) -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +89.48 pp
IMMX: -6.27% · IBO: +83.21%
3M Horizon IBO +981.34 pp
IMMX: -36.66% · IBO: +944.68%
6M Horizon IBO +828.93 pp
IMMX: -16.8% · IBO: +812.13%
1Y Horizon IBO +755.55 pp
IMMX: +107.2% · IBO: +862.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs IBO. Trailing 12-month operating profitability (IMMX 0.0% vs IBO -12621.0%) and valuation multiples (IMMX N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M
IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.6M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMMX BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $657.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $44.4M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMMX vs IBO Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Immix Biopharma, Inc. (IMMX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMMX carries a Unified Composite Score of 48.6/100 (HOLD) at $7.48 (N/M Forward P/E, 0.0% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While IMMX currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY). Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBO leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus $2.6M for IBO. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.

IBO screens cheaper on headline valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus IBO (71.2% ROE) capital efficiency.

In options market volatility and institutional positioning, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 84% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.